CSL (ASX:CSL) Could Be 13% Undervalued After ANDEMBRY Access Expansion

CSL (ASX:CSL) is back in focus after CSL Canada expanded public reimbursement for its hereditary angioedema treatment ANDEMBRY across Quebec, Alberta and key federal programs, while the therapy received a 2026 Prix Galien USA nomination.

CSL shares trade at A$182.30 after a strong 90-day share price return of 54.01%, while the 1-year total shareholder return declined 5.63%, so recent momentum is building even though longer term holders are still sitting on weaker returns.

Scan for other healthcare leaders showing similar momentum shifts with our hand picked 6 healthcare AI stocks, which sit at the intersection of medicine and cutting edge technology.

CSL has surged after the ANDEMBRY news, yet longer term returns remain weak and the shares now sit slightly above the average analyst target. Does that create a better opportunity to enter later, or a case for paying a higher price today?

Most Popular Narrative: 13.2% Undervalued

CSL last traded at A$182.30, while the most followed narrative on the stock anchors fair value at A$210.00. This points to a meaningful valuation gap that investors now have to weigh against recent share price momentum.

CSL is one of Australia’s highest-quality businesses and has a long history of delivering strong returns. It is a global leader in plasma therapies, vaccines and biotechnology, with products that are difficult to replicate and protected by strict regulation. Healthcare demand tends to remain resilient regardless of economic conditions.

See why 41 investors see CSL as 13% undervalued.

Result: Fair Value of A$210.00 (UNDERVALUED)

Still, CSL’s narrative could be tested if product development setbacks slow new therapies, or if currency swings and regulatory decisions hit reported earnings harder than expected.

Find out about the key risks to this CSL narrative.

Next Steps

Mixed signals on CSL’s outlook can feel confusing, so move quickly, review the underlying data, and weigh the 3 key rewards and 1 important warning sign against your own view.

Want more ideas beyond CSL?

If CSL has you rethinking your portfolio, do not stop at one opportunity. Cast the net wider and let fresh ideas compete for your capital.

• Target resilience by filtering for companies with strong finances using our list of solid balance sheet and fundamentals (11 results) so weaker balance sheets do not quietly erode your returns.
• Hunt for value by reviewing the 5 high quality undervalued stocks and see which businesses the market may be pricing too cheaply today.
• Spot potential early movers by scanning the 15 high quality undiscovered gems before attention and pricing catch up.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com